Article
Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2002
Stevenson James P, Sun Weijing, Gallagher Maryann, Johnson Robert, Vaughn David, Schuchter Lynn, Algazy Kenneth, Hahn Stephen, Enas Nathan, Ellis Diane, Thornton Donald, O'Dwyer Peter J
Abstract excerpt
The cryptophycin analogue LY355703 is a potent inhibitor of microtubule polymerization that displays in vitro and in vivo activity in cell lines and tumor xenografts displaying the multidrug-resistant phenotype. In a Phase I trial, 25 patients received LY355703 as a 2-h i.v. infusion on day 1 and day 8 repeated every 3 weeks. Doses were escalated from 0.1 to 2.22 mg/m2 using a modified continual reassessment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.